iBio to Participate in Upcoming Investor Conferences
iBio (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, has announced its participation in two upcoming investor conferences. CEO and Chief Scientific Officer Martin Brenner will deliver a virtual presentation at the H.C. Wainwright 26th Annual Global Investment Conference in New York City, September 9-11, 2024. The presentation will be available on-demand from September 9 and for 30 days after.
Additionally, iBio will attend the 2024 Cantor Global Healthcare Conference in New York City, September 17-19, 2024. CFO Felipe Duran will also be present at both events. Investors interested in one-on-one meetings with Dr. Brenner or Mr. Duran at either conference can schedule by emailing ir@ibioinc.com.
iBio (NYSEA:IBIO), un innovatore di terapie immunologiche a base di anticorpi di precisione guidato dall'IA, ha annunciato la sua partecipazione a due prossimi conferenze per investitori. Il CEO e Direttore Scientifico Martin Brenner presenterà una relazione virtuale alla 26ª Conferenza Annuale di Investimento Globale H.C. Wainwright a New York, dal 9 all'11 settembre 2024. La presentazione sarà disponibile on-demand a partire dal 9 settembre e per 30 giorni dopo.
Inoltre, iBio parteciperà alla Conferenza Sanitaria Globale Cantor 2024 a New York, dal 17 al 19 settembre 2024. Il CFO Felipe Duran sarà presente a entrambi gli eventi. Gli investitori interessati a incontri one-on-one con il Dr. Brenner o il Sig. Duran durante una delle conferenze possono programmare un incontro inviando un'email a ir@ibioinc.com.
iBio (NYSEA:IBIO), un innovador impulsado por IA de terapias inmunológicas de anticuerpos de precisión, ha anunciado su participación en dos próximas conferencias para inversores. El CEO y Director Científico Martin Brenner ofrecerá una presentación virtual en la 26ª Conferencia Anual de Inversión Global H.C. Wainwright en Nueva York, del 9 al 11 de septiembre de 2024. La presentación estará disponible bajo demanda desde el 9 de septiembre y durante 30 días después.
Además, iBio asistirá a la Conferencia Global de Salud Cantor 2024 en Nueva York, del 17 al 19 de septiembre de 2024. El CFO Felipe Duran también estará presente en ambos eventos. Los inversores interesados en reuniones uno a uno con el Dr. Brenner o el Sr. Duran en cualquiera de las conferencias pueden programar una cita enviando un correo electrónico a ir@ibioinc.com.
iBio (NYSEA:IBIO)은 AI 기반의 정밀 항체 면역 요법 혁신 기업으로, 두 개의 다가오는 투자자 회의에 참석한다고 발표했습니다. CEO 겸 최고 과학 책임자인 Martin Brenner는 2024년 9월 9일부터 11일까지 뉴욕에서 열리는 H.C. Wainwright 제26회 연례 글로벌 투자 회의에서 가상 프레젠테이션을 진행합니다. 프레젠테이션은 9월 9일부터 30일 동안 주문형으로 제공됩니다.
또한, iBio는 2024년 9월 17일부터 19일까지 뉴욕에서 열리는 2024 Cantor Global Healthcare Conference에 참석합니다. CFO Felipe Duran도 두 행사에 모두 참석할 예정입니다. Brenner 박사 또는 Duran 씨와의 일대일 미팅을 원하는 투자자는 ir@ibioinc.com으로 이메일을 보내 일정을 조정할 수 있습니다.
iBio (NYSEA:IBIO), un innovateur guidé par l'IA dans le domaine des immunothérapies par anticorps de précision, a annoncé sa participation à deux conférences pour investisseurs à venir. Le PDG et Directeur Scientifique Martin Brenner fera une présentation virtuelle lors de la 26e Conférence Annuelle d'Investissement Mondial H.C. Wainwright à New York, du 9 au 11 septembre 2024. La présentation sera disponible à la demande à partir du 9 septembre et pendant 30 jours après.
De plus, iBio assistera à la Conférence Mondiale de la Santé Cantor 2024 à New York, du 17 au 19 septembre 2024. Le CFO Felipe Duran sera également présent aux deux événements. Les investisseurs intéressés par des réunions individuelles avec Dr. Brenner ou M. Duran lors de l'une des conférences peuvent planifier un rendez-vous en envoyant un e-mail à ir@ibioinc.com.
iBio (NYSEA:IBIO), ein KI-gesteuertes Unternehmen für präzise Antikörper-Immuntherapien, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. CEO und Chief Scientific Officer Martin Brenner wird eine virtuelle Präsentation auf der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright in New York City vom 9. bis 11. September 2024 halten. Die Präsentation wird ab dem 9. September und für 30 Tage danach auf Abruf verfügbar sein.
Zusätzlich wird iBio an der 2024 Cantor Global Healthcare Conference in New York City vom 17. bis 19. September 2024 teilnehmen. CFO Felipe Duran wird ebenfalls bei beiden Veranstaltungen anwesend sein. Investoren, die an persönlichen Gesprächen mit Dr. Brenner oder Herrn Duran während einer der beiden Konferenzen interessiert sind, können einen Termin per E-Mail an ir@ibioinc.com vereinbaren.
- None.
- None.
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today that CEO and Chief Scientific Officer, Martin Brenner, DVM, Ph.D., and Chief Financial Officer, Felipe Duran, will participate in upcoming investor conferences.
Dr. Brenner will give a virtual presentation at the H.C. Wainwright 26th Annual Global Investment Conference, held at the Lotte New York Palace Hotel in New York City, September 9-11, 2024. The presentation will be available on-demand from 7 a.m., Sept. 9, at https://journey.ct.events/view/5a0ac133-a550-4997-9da1-dc0b394219bf and following for 30 days. A replay of the webcast will be available in the investor section of iBio’s website.
iBio will also be attending the 2024 Cantor Global Healthcare Conference in New York City, September 17-19, 2024.
To schedule a one-on-one meeting with Dr. Brenner or Mr. Duran at either of the conferences, please e-mail ir@ibioinc.com.
About iBio, Inc.
iBio is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers, and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets. For more information, visit www.ibioinc.com.
Forward-Looking Statements
Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding the presentations to be made by by Mr. Duran and Dr. Brenner. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, and the risk factors described in the Company’s Annual Report on Form 10-K for the year ended June 30, 2023, and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iBio, Inc. specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Contacts:
iBio, Inc.
Investor Relations
ir@ibioinc.com
Susan Thomas
iBio, Inc.
Media Relations
susan.thomas@ibioinc.com
This press release was published by a CLEAR® Verified individual.
FAQ
What investor conferences will iBio (IBIO) participate in during September 2024?
Who will represent iBio (IBIO) at the upcoming investor conferences?
When and where will Martin Brenner's presentation for iBio (IBIO) be available?
How can investors schedule meetings with iBio (IBIO) executives at the conferences?
